Given the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart failure.
Technology and Heart Failure Therapeutics (THT) 2023 is the conference that focuses on device- and technology-based treatments, while putting these into the perspective of drug-based therapies, thus filling existing gaps. Covering a full range of updates on the current status of drug- and device-based treatments for heart failure across the spectrum, LV ejection fractions, and a late-breaking pivotal studies that have not yet appeared in publications or in treatment guidelines, THT 2023 is an immersive experience in the latest innovations that practitioners can put into practice for treating heart failure.
Concomitantly, with unlimited opportunities for learning and global engagement, THT 2023 offers a future-oriented view of the pipeline for heart failure therapeutics, with a focus on in-development technologies (drugs, devices, monitoring strategies) that are currently in clinical trials — as well as an overview of the rapid advances in artificial intelligence and machine learning and how these technologies will transform the care of heart failure patients in the near future.
CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Documentation of awarded credit is provided for participants in exchange for completed activity evaluations. Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Thaifa Smith at tsmith@crf.org .
By the end of this program, participants should be able to:
• Recount an up-to-date review of the current standards for the care of patients with heart failure across the spectrum of ejection fractions, etiologies, and disease severities.
• Recount the potential role of interatrial shunts in treating HF and preserved EF.
• Recount the differences in different approaches to left-to-right atrial shunts for HF.
• Recount differences in preliminary results from different studies of lef-to-right atrial shunts.
THT 2023 is designed for a multidisciplinary audience that includes anyone interested in heart failure management and a comprehensive overview of existing and investigational interventions. This includes:
• Heart failure specialists
• Cardiac imaging specialists
• Cardiac and vascular surgeons
• Clinical cardiologists
• Fellows in interventional cardiovascular medicine and related fields
• Industry professionals
• Interventional cardiologists
• Medical device experts
• Nurse practitioners
• Physician assistants
• Research scientists
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the course directors of this activity.
In accordance with the accredited continuing education sponsored by Cardiovascular Research Foundation (CRF), all planners, teachers, and authors with control over activity content are required to disclose to the provider any relevant financial relationships (those held by the planner, currently or within the last 24 months) with ineligible companies. Accredited providers are required to provide this information to learners before the start of an activity.
Content Reviewer(s):
Gary S. Mintz, MD — Consultant Fee/Honoraria/ Speaker’s Bureau – Boston Scientific Corporation, Abiomed
Grzegorz L. Kaluza, MD, PhD — Grant Support/Research Contract: Abbott Vascular; Abiomed, Medtronic; 4C Medical; Dura Biotech; InQB8; Ancora Heart; InnovHeart; Mitria; Thubrikar Aortic Valve; Terumo Medical Corporation; Bristol-Myers Squibb; Edwards Lifesciences; Alucent Biomedical; Advanced NanoTechnologies; Adriakaim; Thrombolex; Reflow Medical; Tenaya Therapeutics; Renovacor; Shape Memory Medical; Impulse Dynamics; Occlutech; Neochord; MicroInterventional Devices; Lungpacer; Inozyme; HLT; Deinde Medical; Autonomix; Cardiac Implants; Cagent Medical; Intact Vascular; OncoSec; Soundbite Medical Solutions; VasoRx; LivaNova; Encore Medical; Recardia; Cook Medical; StrideBio; Ethicon, a J&J Company.
Donald Cutlip, MD – Nothing to disclose
Anjelica Scaletta-Resias – Nothing to disclose
Thaifa Smith – Nothing to disclose
CME Independent Review
As a CME provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), CRF is committed to ensuring a fair, balanced view of diagnostic and therapeutic options, and scientific rigor in all its sponsored programs. As such, CRF’s Planning Committee has selected CME associate course directors to provide oversight of the program development planning process to ensure fair, balanced, free of commercial bias, including mitigation of any relevant financial relationships with ineligible companies for planners, faculty and others in control of educational content.
CRF identifies relevant financial relationships and mitigates them before the activity begins.
The CME associate course directors documented that all relevant financial relationships have been mitigated as of December 12, 2022.
This program is sponsored by the Cardiovascular Research Foundation and supported through an unrestricted educational grant by Edwards Lifesciences. The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without influence from commercial supporters.